Articles from Onchilles Pharma

Onchilles Pharma, a private biotech company pioneering next-generation cytotoxic therapeutics that harness the ELANE pathway, today announced the presentation of new preclinical data for its lead drug candidate, N17350, at the American Association for Cancer Research® Annual Meeting 2025 (“AACR”). The presentation highlights N17350’s superior and selective tumor-killing ability compared to standard-of-care chemotherapies in ovarian cancer models, including chemotherapy-resistant tumors, derived from patients.

Onchilles Pharma, a private biotech company pioneering pan-cancer therapeutics that harness the ELANE pathway – a novel innate immune mechanism enabling potent and selective cancer killing with immune preservation – announced today the appointment of Dr. Lev Becker as Chief Scientific Officer and Emily Roberts-Thomson as Senior Vice President of Development Operations.

Onchilles Pharma, a private biotech company pioneering pan-cancer therapeutics that leverage the ELANE pathway, today announced the presentation of new preclinical data from its NEU-002 program at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The event is being held virtually and at the George R. Brown Convention Center in Houston, Texas from November 6-10, 2024.

Onchilles Pharma, a private biotech company developing pan-cancer therapeutics that leverage the ELANE pathway, a novel innate immune mechanism of action for potent and selective cancer killing, announced today that it will present new preclinical data for its NEU-002 program for systemic delivery at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The meeting will be held both virtually and at the George R. Brown Convention Center in Houston from November 8-10, 2024.

Onchilles Pharma, a private biotech company developing cancer therapeutics that leverage a novel innate immune mechanism of action for potent and selective cancer killing, announced today the presentation of new preclinical data for systemically delivered N17465 in an oral presentation and tumor-directed N17350 in a poster presentation at the American Association for Cancer Research® (AACR) Annual Meeting 2024, taking place April 5 to 10 at the San Diego Convention Center.

Onchilles Pharma, a private biotech company developing cancer therapeutics that leverage a novel mechanism of action, announced the presentation of new preclinical data for N17350 at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting being held virtually and at the San Diego Convention Center from November 1-5, 2023. The data presented show the potential for N17350, a first-in-class biologic therapeutic inspired by the immunobiology of neutrophils, to become a major new treatment modality for a wide range of cancer types.

Onchilles Pharma, a private biotech company developing new pan-cancer therapeutics that leverage a novel mechanism of action, announced today the presentation of preclinical data for the N17350 program at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, to be held virtually and at the San Diego Convention Center from November 1-5, 2023.

Onchilles Pharma, a private biotech company developing novel cancer therapeutics that leverage myeloid biology, presented new preclinical data on N17350, a first-in-class biologic therapeutic inspired by ELANE, a protein found in neutrophils that is part of a newly discovered innate cancer-killing pathway. The data demonstrate N17350, as a monotherapy or in combination with checkpoint inhibitors, abrogates tumor growth, induces a robust immune signature with the potential to establish durable remission, and demonstrates no acquired resistance. These data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 taking place in Orlando.

Onchilles Pharma, a private biotech company developing new cancer therapeutics that leverage myeloid biology, announced today the presentation of preclinical data for N17350 at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held April 14 to 19 at the Orange County Convention Center in Orlando, Florida. Onchilles’ lead drug development candidate, N17350, is a first-in-class biologic therapeutic that is inspired by the immunobiology of neutrophils, a key part of the innate immune system, with the potential to be effective against a wide range of cancer types. The company is targeting to start first-in-human clinical trials in 2024.

Onchilles Pharma, a private biotech company developing new cancer therapeutics to modulate myeloid biology, announced today the nomination of its first drug development candidate, N17350, a first-in-class biologic therapeutic that is designed to leverage the immunobiology of neutrophils, a key part in the innate immune system, against a wide range of cancer types. The company is targeting to start first-in-human clinical trials in 2024. Onchilles also disclosed the expansion of its technology platform to design new therapeutics modulating the M2-like TAMs found in multiple solid tumor indications.

Onchilles Pharma announced today the expansion of the company’s scientific team with key leadership appointments. Drs. Christopher Twitty, Ingrid Joseph, and Sonia Feau will be responsible for leading the development of first-in-class therapeutics based on novel neutrophil immunobiology, discovered by the company’s scientific founder Dr. Lev Becker. This groundbreaking work has revealed that therapeutic modulation of this innate immune axis has the potential to selectively kill many cancer cell types while sparing non-cancer cells and for universal anti-cancer activity, independent of genetic mutation.

Onchilles Pharma announced today a $7 Million Series A financing from LYZZ Capital and includes a $500,000 investment from the University of Chicago’s Startup Investment Fund. The proceeds of the financing will be used to develop first-in-class therapeutics to activate a novel pathway of the innate immune system with potential for universal anti-cancer activity, independent of genetic mutation. Research published in today’s issue of Cell is the first to describe this pathway where human neutrophils release catalytically active neutrophil elastase, called ELANE, to selectively kill many cancer cell types while sparing non-cancer cells.